Medivir AB (STU:MVR0) Cyclically Adjusted Book per Share: €0.89 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:MVR0 Medivir AB STU:MVR0
30 GF Score
Price €0.15
GF Value €0.09
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Medivir AB Cyclically Adjusted Book per Share?

Medivir AB STU:MVR0 -1.28% 30 Cyclically Adjusted Book per Share is €0.89 as of Mar. 2026. GuruFocus rates STU:MVR0 with a GF Score™ of 30/100 and a GF Value™ of €0.09 (Significantly Overvalued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Medivir AB's adjusted book value per share for the three months ended in Mar. 2026 was €0.033. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €0.89 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Medivir AB's average Cyclically Adjusted Book Growth Rate was -30.80% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -18.90% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -11.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Medivir AB was 0.10% per year. The lowest was -18.90% per year. And the median was -3.10% per year.

As of today (2026-08-04), Medivir AB's current stock price is €0.1542. Medivir AB's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was €0.89. Medivir AB's Cyclically Adjusted PB Ratio of today is 0.17.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Medivir AB was 2.89. The lowest was 0.03. And the median was 0.31.


Medivir AB  (STU:MVR0) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Medivir AB's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=0.1542/0.89
=0.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Medivir AB was 2.89. The lowest was 0.03. And the median was 0.31.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Medivir AB Cyclically Adjusted Book per Share Related Terms


Medivir AB Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Medivir AB's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medivir AB Cyclically Adjusted Book per Share Chart

Medivir AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.87 1.82 1.78 1.36 0.95

Medivir AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.38 1.26 1.10 0.95 0.89

STU:MVR0 vs VRTX, REGN, RVMD: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Medivir AB's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medivir AB Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medivir AB's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Medivir AB's Cyclically Adjusted PB Ratio falls into.


STU:MVR0
30GF Score
Medivir AB STU:MVR0
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medivir AB Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Medivir AB's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.033/133.5600*133.5600
=0.033

Current CPI (Mar. 2026) = 133.5600.

Medivir AB Quarterly Data

Book Value per Share CPI Adj_Book
201606 3.728 101.019 4.929
201609 3.474 101.138 4.588
201612 4.493 102.022 5.882
201703 2.768 102.022 3.624
201706 2.388 102.752 3.104
201709 2.159 103.279 2.792
201712 1.728 103.793 2.224
201803 1.598 103.962 2.053
201806 1.330 104.875 1.694
201809 1.122 105.679 1.418
201812 0.830 105.912 1.047
201903 0.664 105.886 0.838
201906 0.624 106.742 0.781
201909 0.561 107.214 0.699
201912 0.488 107.766 0.605
202003 0.410 106.563 0.514
202006 0.391 107.498 0.486
202009 0.406 107.635 0.504
202012 0.386 108.296 0.476
202103 0.484 108.360 0.597
202106 0.462 108.928 0.566
202109 0.441 110.338 0.534
202112 0.402 112.486 0.477
202203 0.347 114.825 0.404
202206 0.312 118.384 0.352
202209 0.287 122.296 0.313
202212 0.258 126.365 0.273
202303 0.228 127.042 0.240
202306 0.186 129.407 0.192
202309 0.154 130.224 0.158
202312 0.186 131.912 0.188
202403 0.167 132.205 0.169
202406 0.139 132.716 0.140
202409 0.111 132.304 0.112
202412 0.090 132.987 0.090
202503 0.083 132.825 0.083
202506 0.064 133.699 0.064
202509 0.053 133.480 0.053
202512 0.032 133.390 0.032
202603 0.033 133.560 0.033

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €0.89 mean?
Medivir AB (STU:MVR0) has a Cyclically Adjusted Book per Share of €0.89 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Medivir AB and its competitors.
Is Medivir AB's Cyclically Adjusted Book per Share too high?
Medivir AB's current Cyclically Adjusted Book per Share is €0.89. Overall, Medivir AB has a GF Score™ of 30/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medivir AB's Cyclically Adjusted Book per Share compare to VRTX and REGN?
Medivir AB's Cyclically Adjusted Book per Share of €0.89 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Medivir AB and its competitors. Medivir AB's current Cyclically Adjusted Book per Share is €0.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medivir AB stock overvalued right now?
Based on GuruFocus' analysis, Medivir AB (STU:MVR0) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.09, compared to a current price of €0.15 — trading 71.3% above its estimated fair value. The current Cyclically Adjusted Book per Share is €0.89. Medivir AB's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Medivir AB (STU:MVR0), the current Cyclically Adjusted Book per Share is €0.89 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medivir AB (STU:MVR0) Overvalued in 2026?

Based on GuruFocus' analysis, Medivir AB stock appears to be overvalued. The current stock price of €0.15 is trading 71.3% above its estimated GF Value™ of €0.09. GuruFocus considers Medivir AB to be Significantly Overvalued.

Key valuation signals for STU:MVR0:

  • Cyclically Adjusted Book per Share: €0.89
  • GF Value™: €0.09 vs. price of €0.15 (71.3% above fair value)
  • GF Score™: 30/100 with 2 warning signs

No single metric tells the full story. See the STU:MVR0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Medivir AB Business Description

Other Exchanges MVIR:SwedenMVIRs:UK0GP7:UK
Address Lunastigen 5, PO Box 1086, 2nd floor, Huddinge, SWE, 141 22
Medivir AB develops drugs with a focus on cancer, where unmet medical needs are high. The company is concentrating on the development of fostroxacitabine bralpamide (fostrox), a liver-targeted inhibitor of DNA replication that selectively delivers the cell-killing agent to the tumor while minimizing potentially harmful effects on normal cells. It has developed two pharmaceutical products: Xerclear, used for treating labial herpes (cold sores), and Olysio, which have reached the market. Medivir also also has four out-licensed projects Xerclear, MIV-701, MBLI/MET-X. Geographically, it generates its maximum revenue from Europe and other regions.
30GF Score

Get the complete analysis for STU:MVR0

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.15
Price
€0.09
GF Value